Insider Buying: Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director Buys 9,000 Shares of Stock

Nymox Pharmaceutical Corp (NASDAQ:NYMX) Director James George Robinson purchased 9,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average price of $1.46 per share, with a total value of $13,140.00. Following the purchase, the director now owns 3,391,550 shares in the company, valued at $4,951,663. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

James George Robinson also recently made the following trade(s):

  • On Wednesday, June 5th, James George Robinson purchased 11,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average price of $1.55 per share, with a total value of $17,050.00.
  • On Monday, June 3rd, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average price of $1.62 per share, with a total value of $14,580.00.
  • On Thursday, May 30th, James George Robinson purchased 8,500 shares of Nymox Pharmaceutical stock. The shares were acquired at an average price of $1.76 per share, with a total value of $14,960.00.
  • On Tuesday, May 28th, James George Robinson purchased 9,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average price of $1.68 per share, with a total value of $15,120.00.
  • On Friday, May 24th, James George Robinson purchased 8,000 shares of Nymox Pharmaceutical stock. The shares were acquired at an average price of $1.59 per share, with a total value of $12,720.00.

NASDAQ:NYMX traded up $0.05 during trading hours on Friday, reaching $1.58. 863 shares of the company’s stock were exchanged, compared to its average volume of 84,882. The company has a current ratio of 8.04, a quick ratio of 8.01 and a debt-to-equity ratio of 0.03. Nymox Pharmaceutical Corp has a 1-year low of $1.25 and a 1-year high of $3.90.

Nymox Pharmaceutical (NASDAQ:NYMX) last issued its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. Nymox Pharmaceutical had a negative return on equity of 175.82% and a negative net margin of 6,101.69%.

A number of hedge funds and other institutional investors have recently modified their holdings of NYMX. State of Wisconsin Investment Board boosted its stake in shares of Nymox Pharmaceutical by 29.7% during the 1st quarter. State of Wisconsin Investment Board now owns 44,600 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 10,200 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Nymox Pharmaceutical by 0.4% during the 1st quarter. BlackRock Inc. now owns 1,641,663 shares of the biopharmaceutical company’s stock worth $3,234,000 after purchasing an additional 7,336 shares during the last quarter. Willow Creek Wealth Management Inc. boosted its stake in shares of Nymox Pharmaceutical by 94.3% during the 1st quarter. Willow Creek Wealth Management Inc. now owns 34,124 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 16,562 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Nymox Pharmaceutical by 10.8% during the 4th quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 13,103 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Nymox Pharmaceutical by 130.1% during the 4th quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 83,925 shares during the last quarter. 5.66% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2019/06/14/insider-buying-nymox-pharmaceutical-corp-nasdaqnymx-director-buys-9000-shares-of-stock.html.

About Nymox Pharmaceutical

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

Further Reading: What is Depreciation?

Insider Buying and Selling by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.